Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Depression, Depression Severe, Depression Acute, Depression and Suicide, Suicidal Ideation
Interventions: Ketamine, Sodium Chloride 0.9%; Drug
Lead sponsor: MercyOne Des Moines Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: There is no Focus on Any Specific Condition
Interventions: Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline; Procedure · Other · Device + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 90 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pain Management
Interventions: ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline; Other · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Migraine
Interventions: OnabotulinumtoxinA, Normal saline (placebo); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dysphagia, Dysphonia, Postoperative Pain
Interventions: Racemic Epinephrine, Placebo (for racemic epinephrine); Drug
Lead sponsor: Andrew Chung; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chest Pain, Acute Coronary Syndrome
Interventions: Dexmedetomidine, Normal Saline, Intranasal cocaine; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: MEDI-522, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 29
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more

Conditions: Infiltration of Peripheral IV Therapy
Interventions: ivWatch Model 400 with Milky Way Sensor; Device
Lead sponsor: ivWatch, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Newport News, Virginia

Conditions: Stroke
Interventions: Intranasal Insulin, Intranasal saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Periodontal Diseases
Interventions: Xylocaine 2 % with 1:100,000 epinephrine, Bupivicaine 0.5% with 1:200,000 epinephrine, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions: OnabotulinumtoxinA, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mountlake Terrace, Washington

Conditions: Headache
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions: RiaStAP, Saline; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 1 Day to 1 Year
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Pilonidal Disease
Interventions: Irrisept (0.05% chlorhexidine gluconate), Normal Saline; Device · Other
Lead sponsor: Yosef Nasseri, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Skin Aging, Skin Wrinkling
Interventions: PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo); Drug
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions: Ipratropium Bromide, Normal Saline (Placebo); Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 8 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Prosper, Texas

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: COVID-19
Interventions: Crizanlizumab, 0.9% saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use, Surgical Recovery, Vaginal Hysterectomy, Prolapse Pelvic, Postoperative Pain
Interventions: Bupivacaine-epinephrine, Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Raleigh, North Carolina

Search by objective public record fields.

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Antegrade Versus Retrograde IV for Blood Draws

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

Dexmedetomidine for Reversal of Cocaine's Effects on the Heart

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

Milky Way Sensor: Device Validation for Infiltrated Tissues

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Ketamine for Acute Migraine in the Emergency Department

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Effect of Ipratropium Bromide on EILO

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Crizanlizumab for Treating COVID-19 Vasculopathy

Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse